Glioblastoma (GBM) is the most aggressive primary brain tumor with high proliferation and invasion and easy recurrence after surgery.1 Following advanced standard treatment, including resection followed by radio‐ and chemotherapy, the median survival time of GBM patients is only ≈14 months.2 Epidermal growth factor receptor (EGFR) is one of the important genes driving GBM. Here, EGFR is linked to glioblastoma.